Clinical Trial Update: A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements [Phase 1]

View source ↗

Summary

Phase 1 trial comparing insulin pegispro (LY2605541) versus glargine in type 1 diabetes to assess meal-time insulin requirements; study completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Glargine (insulin glargine)
• insulin peglispro (LY2605541) (insulin peglispro)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED | Results posted: 2019-03-01